Codagenix said that it has completed a $25 million Series B extension financing, with funds primarily going to support development of its CodaVax-RSV intranasal live attenuated vaccine against respiratory syncytial virus. The FDA recently granted Fast Track designation to CodaVax-RSV. Investors in this funding round included the Serum Institute of India, Euclidean Capital, and Adjuvant Capital.
In June 2022, Codagenix announced that the FDA had cleared the IND for CodaVax-RSV and that the company was planning a Phase 1 study in children aged 6 months to 5 years. According to the new announcement, the Phase 1 study is expected to begin in “early 2023.” Codagenics also noted that a Phase 3 trial supported by the Serum Institute of India and the World Health Organization is evaluating the company’s CoviLiv intranasal vaccine against COVID-19.
Codagenix CEO J. Robert Coleman commented, “It is exciting to now have the Serum Institute of India as a direct investor, building upon our successful partnership in the development of CoviLiv and, of course, we thank Euclidean Capital and Adjuvant Capital for their continued support and belief in our differentiated platform.”
Read the Codagenix press release.
